#generative-ai

Moderna and Merck's individualized cancer vaccine program appears to have overcome years of skepticism, according to STAT. Anthropic's revenue climbed sharply even as its flagship model reportedly loses ground to cheaper rivals, a tension one developer described as forcing harder choices about AI coding costs. Health policy shifted on several fronts: a Medicaid precedent that could reach far beyond its original target, a new FDA nominee, and a promised FDA guidance on generative AI devices.

Leaked internal messages reveal Sam Altman strategized in 2023 to release a local GPT-3-class model to suppress competitors and dry up funding; separately, a security researcher found a WordPress RCE using GPT-5.6 for $25, and Kimi K3's 2.8T open-weights release continued pressure on closed frontier labs. In pharma, Eli Lilly's psychedelics acquisition drew further industry analysis, GSK axed its key cough drug candidate, and a state Medicaid audit exposed PBM cost-obscuring tactics. The economy section covers Waymo safety data, the UK as a cautionary macro tale, and Basel III's hidden fragility inside bank holding companies.